ALX 009

Drug Profile

ALX 009

Alternative Names: ALX-009

Latest Information Update: 18 Dec 2015

Price : $50

At a glance

  • Originator Alaxia
  • Class Biological proteins
  • Mechanism of Action Cell membrane modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 20 Nov 2015 Alaxia plans a phase I trial for Cystic Fibrosis in France (NCT02598999)
  • 20 Nov 2015 New profile created from NCT02598999
  • 01 Nov 2015 Phase-I clinical trials in Cystic fibrosis in France (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top